Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
February 25, 2019
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
February 19, 2019
Glenmark Pharmaceuticals receives ANDA approval for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg
February 11, 2019
Glenmark Pharmaceuticals receives tentative ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)
February 7, 2019
Search Result :-Is an investigational new drug that has not been approved for commercial distribution in the United States.
US Media Contact
For media inquiries only, please contact An Phan, Corporate Communications.
For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.